AZD4360

DRUG2 trials

Sponsors

AstraZeneca AB, AstraZeneca

Conditions

Biliary Tract CancerGastric CancerGastroesophageal Junction CancerPancreatic Ductal Adenocarcinoma

Phase 1

Study for AZD4360 in Participants With Advanced Solid Tumours

Active, not recruitingNCT06921928

AstraZenecaBiliary Tract Cancer, Gastric Cancer, Gastroesophageal Junction Cancer +1

Start: 2025-04-29End: 2027-12-16Updated: 2026-07-31

A Phase I/II Open-label Dose Escalation and Dose Expansion Study to Evaluate the Safety, Pharmacokinetics, Pharmacodynamics, and Efficacy of AZD4360 in Adult Participants with Advanced Solid Tumours

RecruitingCTIS2024-518281-27-00

AstraZeneca ABBiliary Tract Cancer, Gastric Cancer, Gastroesophageal Junction Cancer +1

Start: 2026-01-09Target: 17Updated: 2026-01-06